After IPO, new deals, Adalta entering clinic with shark antibodies
By Tamra Sami
Wednesday, November 23, 2016
PERTH, Australia – Following its IPO in August, Melbourne-based Adalta Pty Ltd. inked two deals this month, and is now moving to the clinic with its human version of the shark antibody platform, the i-body.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.